Completed PHASE1 INTERVENTIONAL 1-arm NCT01385423

Haploidentical Donor Natural Killer Cell Infusion With IL-15 in Acute Myelogenous Leukemia (AML)

Haploidentical Donor Natural Killer (NK) Cell Infusion With Intravenous Recombinant Human IL-15 (rhIL-15) in Adults With Refractory or Relapsed Acute Myelogenous Leukemia (AML)

Sponsor: Masonic Cancer Center, University of Minnesota

Conditions Acute Myelogenous Leukemia Myelodysplastic Syndrome

Interventions Intravenous Recombinant Human IL-15 (rhIL-15) Preparative Regimen

Updated 7 times since 2017 Last updated: Jul 21, 2025 Started: Sep 30, 2011 Primary completion: Mar 31, 2015 Completion: Mar 31, 2015

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01385423, this PHASE1 trial focuses on Acute Myelogenous Leukemia and Myelodysplastic Syndrome and remains completed. Sponsored by Masonic Cancer Center, University of Minnesota, it has been updated 7 times since 2011, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

7 versions recorded

Aug 2025 — Present [monthly]

Completed PHASE1
Sep 2024 — Aug 2025 [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Completed PHASE1
Jan 2017 — Feb 2017 [monthly]

Completed PHASE1

First recorded

Sep 2011

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Masonic Cancer Center, University of Minnesota

Data source: Masonic Cancer Center, University of Minnesota

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Minneapolis, United States